Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin renal hemodynamics study with adenosine blockade in chronic kidney disease and type 2 diabetes
NL-OMON49123Phase 4Withdrawn
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), diabetic glomerulosclerosis and 1 more (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Change in measured glomerular filtration rate. Planned start Mar 2020; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)diabetic glomerulosclerosishypertension (HTN)
Beyond the preview
Go deeper on NL-OMON49123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49123.